ESPE Abstracts

Background: Precocious puberty is defined by the development of secondary sexual characteristics before the age of 8 in girls and before the age of 9 in boys. if not diagnosed and treated at an early stage, precocious puberty can compromise final adult height and trigger psychological disturbances. Gonadotropin- releasing hormone analogs (GnRHa) contributes to achievement of target final height by reducing the acceleration of bone maturation.

Objectives: To analyze clinical and para clinical features in patients with precocious puberty, effect of triptoreline in improvement of secondary sexual characteristics and predicted adult height (PAH) after 6 months of treatment.

Subjects and Method: Case-series study included 49 patients with precocious puberty at Vinmec Central Park International Hospital from June 2019 to March 2020.

Results: After 6 months of treatment, secondary sexual characteristics reduced or ceased, acceleration of bone age decreased, sexual hormonal levels fell below puberty range. In addition, PAH improve significantly in female group with initiation of treatment before the age of 8.

Conclusions: Triptoreline decreases secondary sexual characteristics such as menarche, breast development, pubic hair, body odor and reduces the concentration of hormons (FSH, LH, Estradiol, Testosterone). In addition, Triptoreline increased PAH resulting in improving final adult height.